Overview

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:
0

Participant gender:
Female

Summary

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

October 6 University

Treatments:

Metformin
Vildagliptin

Criteria

Inclusion Criteria:

-Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of
Health criteria.

Exclusion Criteria:

- Patients with history of diabetes mellitus (Type 1 or 2).

- Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease;
cancer, acute cardiovascular event within last three months

- Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4)
inhibitors

- Eating disorders (anorexia, bulimia) or gastrointestinal disorders